title: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis.
abstract: OBJECTIVE
  Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described.
  
  
  CONCLUSIONS
  Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies.
  
  
  CONCLUSIONS
  Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.
authors.affiliation: Pharmacy Consultant II, Clinical Pharmacy Services, Commonwealth Medicine, University of Massachusetts Medical School, Worcester, MA 01545, USA. David.gammon@umassmed.edu
authors.forename: David C
authors.initials: DC
authors.lastname: Gammon
authors.forename: Traci
authors.initials: T
authors.lastname: Dutton
authors.forename: Bilal
authors.initials: B
authors.lastname: Piperdi
authors.forename: Jason
authors.initials: J
authors.lastname: Zybert
authors.forename: Steven H
authors.initials: SH
authors.lastname: Wolfe
authors.forename: Erin
authors.initials: E
authors.lastname: Nguyen
authors.forename: Dalia
authors.initials: D
authors.lastname: Sbat
authors.forename: Venu G
authors.initials: VG
authors.lastname: Pillarisetty
authors.forename: Mary
authors.initials: M
authors.lastname: Sullivan
authors.forename: Giles F
authors.initials: GF
authors.lastname: Whalen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral / Q000379:methods; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D010534:Peritoneal Neoplasms / Q000628:therapy*; D011787:Quality of Health Care; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin